Comparative nasal effects of bradykinin and histamine: influence on nasal airways resistance and plasma protein exudation

K Rajakulasingam, R Polosa, L C K Lau, M K Church, S T Holgate, P H Howarth

Abstract

Background—Bradykinin may contribute to the pathogenesis of allergic rhinitis. Like histamine, nasal challenge with bradykinin induces rhinorrhoea, nasal blockage, and plasma protein leakage. Their comparative nasal potencies have not, however, been fully elucidated.

Methods—Three double blind, randomised, placebo controlled and crossover studies were undertaken to compare objectively the nasal effects of bradykinin, histamine, and vehicle.

Results—Both bradykinin and histamine produced dose dependent increases in nasal airways resistance (NAR). There was no significant difference in the effects of bradykinin and histamine on NAR at any dose level. On a molar basis, however, bradykinin was 6.98 times more potent than histamine in inducing a 50% increase in NAR. Nasal challenge with bradykinin and histamine also induced significant rhinorrhoea compared with vehicle. The amount of rhinorrhoea induced by histamine was significantly greater than that induced by bradykinin at any dose level. Bradykinin and histamine induced dose dependent nasal pain and nasal itch respectively. When administered as single doses both bradykinin (1.9 μmol) and histamine (1.9 μmol) induced significantly greater rhinorrhoea compared with the vehicle. The volume of rhinorrhoea secretions induced by histamine was 29% greater than that induced by bradykinin. In contrast, although NAR was increased significantly more by histamine than by the vehicle, the effect of bradykinin on NAR was significantly greater than histamine and vehicle in both magnitude and duration of effect. The incremental effect of bradykinin on lavage albumin levels was also significantly greater than both histamine and vehicle.

Conclusions—This study shows that the nasal vascular effects of histamine are less prominent than its actions on rhinorrhoea, and that the greater obstructive effect of bradykinin than histamine on NAR may contribute to the relative lack of efficacy of H₁ antihistamines on nasal blockage in clinical disease.

Allergic rhinitis is a common condition characterised by symptoms of nasal itch, sneezing, rhinorrhoea, and nasal blockage. As the local release of histamine has been identified in both the immediate and late nasal response to allergen challenge, and nasal insufflation with histamine induces nasal itch, sneeze, rhinorrhoea, and transient nasal blockage, it has been implicated in the pathophysiology of rhinitis. While the local release of histamine from activated mast cells or basophils within the nasal mucosa can explain many of the symptoms of rhinitis, the involvement of non-histamine mediators in this disease is suggested by the incomplete therapeutic efficacy of H₁ antihistamines, particularly with respect to nasal blockage. A prominent candidate among the non-histaamine mediators for a major role in rhinitis is bradykinin, a potent vasoactive nonapeptide formed as a cleavage product from the action of plasma kallikreins on high molecular weight kininogen.

Kinin activity is present in increased amounts in nasal lavage fluid after early and late phases of nasal allergen provocation. Its activity was also found to be increased in naturally occurring seasonal allergic rhinitis and during natural and induced rhinoviral colds. Nasal insufflation with bradykinin elicited many of the features of rhinitis including nasal blockage, rhinorrhoea, and increased plasma vascular leakage. As the release of kinins into nasal lavage fluid is coincidental with the onset of symptoms of rhinitis after local allergen challenge, and as these kinins are known to exhibit a range of proinflammatory actions, they have also been causally implicated in the pathogenesis of allergic rhinitis.

There have been few studies directly comparing the nasal effects of bradykinin with other mediators identified in association with rhinitis, and only one study comparing the nasal effects of bradykinin and histamine has been published. This study did not, however, attempt to match the agonists on a molar basis and did not investigate the comparative effects of these agonists on plasma protein leakage. We have therefore undertaken a double blind, randomised study to compare the nasal effects of bradykinin and histamine by investigating their effects on nasal airways resistance (NAR), rhinorrhoea, sensory nasal symptoms of pain and itch, and plasma protein exudation.
Comparative nasal effects of bradykinin and histamine

Methods

Subjects

Ten non-rhinitic (asymptomatic), non-smoking, non-atopic healthy volunteers (six men and four women) with a mean age of 27 years participated in the study. All subjects refrained from taking any form of medications for one month before and throughout the study period. None of the subjects had a history of recent upper respiratory tract infection, nasal polyps, infective rhinitis, nasal surgery, or nasal deformities, and all gave written informed consent. The study was approved by the Southampton Hospitals and University joint ethical subcommittee.

Challenge solutions

Bradykinin triacetate acid (Nova Biochem Ltd, Nottingham, UK) and histamine acid phosphate (Sigma, Poole, Dorset, UK) were dissolved in 10% ethanol in 0.9% sodium chloride and 0.9% sodium chloride respectively to produce a concentration range of 0.77, 3.85, and 7.7 mg/ml (0.73, 3.63, and 7.26 x 10^-3 mol/l) and 2.0, 4.0, and 8.0 mg/ml (6.5, 13.0, and 26.0 x 10^-3 mol/l) respectively. These solutions were chosen from previous dose-response studies. For the second and third phases of the study bradykinin and histamine were dissolved in the relevant diluents to produce concentrations of 7.7 mg/ml (7.26 x 10^-3 mol/l) and 2.25 mg/ml (7.32 x 10^-3 mol/l) respectively. The purity of the synthetic bradykinin was confirmed by high performance liquid chromatography as described previously.

Study design

The study was conducted in three phases.

Phase 1: Dose-response study

The subjects attended on three occasions at the same time of day to receive nasal challenge with incremental doses of either bradykinin (0.19 μmol (0.2 mg), 0.95 μmol (1.0 mg), and 1.9 μmol (2.0 mg)), histamine (1.7 μmol (0.52 mg), 3.4 μmol (1.04 mg), and 6.8 μmol (2.08 mg)), or vehicle placebo in a double blind, randomised, crossover fashion. Each visit was separated by at least one week. After a 15 minute rest, measurements were made of baseline NAR (mean of three measurements) by active posterior rhinomanometry using a Mercury NR6 Rhinomanometer (Mercury Instruments, Glasgow, UK) as described previously. This method of measurement of NAR has a coefficient of variation of repeated measurements of 10.7%. Subjects then underwent nasal challenge with the vehicle followed by incremental doses of bradykinin or histamine at 15 minute intervals until the top challenge dose had been achieved. Nasal challenge was undertaken bilaterally using a hand held pump spray delivering 0.13 ml/activation with a coefficient of variation of output of 8.4%. The spray was placed in one nostril while occluding the other and activated once during quiet inspiration. The procedure was then repeated in the opposite nostril. The doses of the agonist were equally divided between nostrils. After each challenge repeat measurements of NAR were made at 3, 5, 10, and 15 minutes and subjects recorded the nasal pain or discomfort and nasal itch on a 10 cm visual analogue scale. Rhinorrhoea was measured 45 seconds before each measurement of NAR by collecting blown secretions on preweighed tissues. The tissue towels were then immediately reweighed and the weight of secretion calculated by subtraction. The symptom of sore throat was recorded as present or absent and the number of sneezes was counted.

Phase 2: Time course study

Each of the 10 subjects attended on three occasions at the same time of day. At each visit, separated by at least one week, measurements were made of baseline NAR by active posterior rhinomanometry after a 15 minute rest. Subjects then underwent nasal challenge with a single dose of bradykinin (1.9 μmol), histamine (1.9 μmol), or vehicle placebo in a double blind, randomised, crossover fashion. The dose of histamine was selected on an equimolar basis to the selected dose of bradykinin. Repeat measurements of NAR were made at 3, 5, 10, 15, 20, 25, 30, 35, and 40 minutes after the challenge and subjects recorded the nasal pain or discomfort and nasal itch on a 10 cm visual analogue scale. Rhinorrhoea was measured as described above.

Phase 3: Nasal lavage study

Eight subjects (five men) attended on a further three occasions having been randomly allocated to receive nasal challenge with the same single dose of bradykinin, histamine, or vehicle in a double blind, crossover design. Subjects were instructed to tilt their heads backwards about 30° from the horizontal while in the sitting position, to hold their breath, and to refrain from swallowing. Two and a half ml of 0.9% prewarmed saline were then instilled into each nostril and after 10 seconds the subjects flexed their necks and expelled the mixture of mucus and saline into a collection vessel. Samples were immediately sieved to remove mucus plugs and stored on ice until the conclusion of the experiment and then frozen at -20°C for protein analysis. At each attendance sequential nasal lavage was performed bilaterally five times, at one minute intervals, before nasal insufflation challenge with the fifth sample which was used for baseline analysis. Repeated saline nasal lavages were performed at 3, 5, 10, 15, 20, 25, 30, 35, and 40 minutes after the challenge.

Total protein and albumin measurement

Total protein concentrations were measured in 0.25 ml replicates of nasal lavage fluid by the method of Bradford using Coomassie Blue G-250 reagent (Pierce, Rockford, Illinois, USA) as indicator. Absorbancy read at 595 nm was compared with a standard curve constructed with bovine serum albumin...
(Sigma, Poole, UK) to give absolute protein concentrations. Albumin levels were measured by rocket immunoelectrophoresis; 3 μl aliquots of nasal lavage fluid were introduced into wells cut in agarose gel and subjected to electrophoresis (4 V/cm) for 20 hours into a “window” of agarose containing 1-18 μl/ml rabbit antihuman albumin antibody (Nordic, Tilburg, Netherlands). Immunoprecipitates were stained with Coomassie Brilliant Blue. Albumin levels were quantified by comparison with standard curves constructed using human albumin (Sigma, Poole, UK). The sensitivity of the albumin assay was 1 μg/ml and the coefficient of variation of repeated measurements was 5%.

DATA ANALYSES
Baseline measurements of NAR (Pa cm−1 s), lavage albumin, and total protein on the different challenge days were compared between days using the Friedman’s two way ANOVA test. To compare the dose-response changes in NAR, the maximum increase in NAR for each subject was plotted against the dose of agonist on a logarithmic scale and the provocation dose causing a 50% increase in NAR (PD50) was derived by linear interpolation and geometric mean values calculated for each group. The nasal response to each agonist was compared as PD50 values with the Student’s paired t test after logarithmic transformation of the data. The time dependent changes in NAR, albumin, and total protein following nasal challenge with single dose of bradykinin, histamine, and vehicle placebo were compared both within groups and between groups by Friedman’s test, as the changes at single time points for each agonist were not normally distributed. To assess differences between treatments, the mean area under the curve (AUC) for each challenge period of observation was calculated and compared with the Wilcoxon’s signed rank test for paired data. The Wilcoxon’s signed rank test was also used for comparisons of the effects of bradykinin, histamine, and vehicle placebo challenges on the quantity of nasal secretions, the number of sneezes, and the visual analogue scores for nasal pain and nasal itch. Values were expressed as mean (SE) or median values with ranges as appropriate. A p value of <0.05 was accepted as the level of significance.

Results
PHASE 1
There were no significant differences between the baseline NAR measurements (Pa cm−1 s) on any of the three challenge days (p > 0.05). Nasal challenge with incremental doses of both bradykinin and histamine induced a dose dependent increase in NAR in all 10 subjects (p < 0.001) while vehicle placebo was without significant effect (fig 1). At the doses selected there were no significant differences in the effects of bradykinin and histamine on NAR at any dose level (p > 0.05) whether assessed as peak response or AUC.

The mean PD50 value for bradykinin was 637.3 μg and this did not differ significantly from the corresponding value with histamine of 1287.3 μg. Comparison on a molar basis, however, identified PD50 values of 0.6 μmol and 4.2 μmol for bradykinin and histamine respectively (table) (p < 0.01), with bradykinin being 6-98 (0.56–59.1) times more potent than histamine in inducing the changes in NAR. Similarly analysis of the AUC data on a molar basis identified bradykinin to be 5.4 (0.72–17.43) times more potent than histamine in inducing nasal obstruction. No PD50 could be calculated after nasal challenge with the vehicle as no increase in NAR occurred. Both bradykinin and histamine also induced significantly greater rhinorrhoea than the vehicle (p < 0.05) with median secretion weights of 212, 260, and 280 mg for bradykinin and 360, 390, and 440 mg for histamine (fig 2). Histamine induced rhinorrhoea was significantly greater than that induced by bradykinin at all dose levels (p < 0.05).

Bradykinin induced significant nasal pain (p < 0.05) with median values of 2, 3, and 3 cm on the visual analogue scale (fig 3A). Maximal nasal pain was felt 3–5 minutes after the challenge and lasted for 10 minutes. Histamine and vehicle did not induce nasal pain. Histamine, however, induced significant nasal itch with median values on the visual

<table>
<thead>
<tr>
<th>PD50 values for bradykinin and histamine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject no.</td>
</tr>
<tr>
<td>-----------------</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>7</td>
</tr>
<tr>
<td>8</td>
</tr>
<tr>
<td>9</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>Geometric mean</td>
</tr>
</tbody>
</table>

BK—bradykinin; H—histamine.

Figure 1. Dose dependent changes in nasal airways resistance (Pa cm−1 s) following nasal challenge with incremental doses of bradykinin (●), histamine (●) and 10% ethanol saline (○). Each result is mean (SE) of observations in 10 subjects.
Comparative nasal effects of bradykinin and histamine

The effect of histamine was transient (less than five minutes) while the increase in NAR with bradykinin was maintained throughout the 40 minute period of observation. The AUC for the time response plot for bradykinin on NAR was significantly greater than for either histamine (p < 0.05) or the vehicle (p < 0.005). Bradykinin and histamine induced significant rhinorrhoea compared with the vehicle (p < 0.05) with median secretion weights of 376 (range 83–597) mg and 484 (range 96–1700) mg respectively. The volume of rhinorrhoea secretions induced by histamine was significantly greater than that induced by bradykinin (p < 0.05).

Bradykinin induced significant nasal pain (p < 0.05) with median values of 2.8 (range 0.4–7.2) cm on the visual analogue scale. Histamine, however, induced significant nasal itch with a median value of 2.2 (range 1–4) cm. Three subjects complained of sore throat lasting for up to 25 minutes after bradykinin challenge. Four subjects sneezed more than twice in response to histamine challenge. No such response was observed after bradykinin and vehicle nasal challenges.

**PHASE 2**

There were no significant differences between baseline NAR measurements on any of the three challenge days (p > 0.05). Both bradykinin and histamine produced significant increases in NAR compared with the vehicle, with mean maximal percentage increments three minutes after the challenge of 88% (p < 0.001) and 25% (p < 0.05) respectively.

Figure 2 Changes in weight of rhinorrhoea secretions following nasal challenge with incremental doses of bradykinin (open bars), histamine (hatched bars), and vehicle placebo (horizontal hatched bars). Each column represents the median values from 10 subjects.

Figure 3 Reporting of (A) nasal pain and (B) nasal itch following nasal challenge with incremental doses of bradykinin (open bars), histamine (hatched bars), and vehicle placebo (horizontal hatched bars). Each column represents the median values from 10 subjects.

analogue scale of 1, 2, and 2 cm (fig 3B). Maximal nasal itch was felt three minutes after the challenge. Bradykinin and vehicle were without significant effect. Eight subjects sneezed more than twice in response to histamine challenge while no such response was observed after challenge with bradykinin or vehicle. Four subjects complained of a sore throat lasting up to 15 minutes after bradykinin challenge.
Discussion

By performing both a dose-response comparison and comparison of single, equimolar dose challenges in the same subjects, it has been possible to relate the vascular and non-vascular actions of bradykinin and histamine. This study shows that consistent with the findings reported by Doyle et al in the only other comparative study of these agonists within the nose. The study indicated that histamine, when given in incremental doses, was more potent than bradykinin in inducing nasal blockage. While this might visually appear so at the highest doses investigated in the present study (fig 1), there was no significant difference between the two agonists at any time after the challenge. It is of interest, however, that histamine challenge has been shown to produce elevated kinin levels in nasal lavage specimens and an element of nasal blockage after repeated challenge with histamine could relate to an additional action of kinins rather than the action of histamine itself. This and the methods of comparison may explain the dichotomous results of Doyle et al. They compared the cumulative dose effect (mg for mg) of these agonists; the doses were not compared on an equimolar basis as in the present study and no comparative time course study using equimolar doses of bradykinin and histamine was performed. As the molecular weight of histamine is 3-45 times less than that of bradykinin, the molar dose of histamine was in fact greater than that of bradykinin and their results are thus not comparable to those presented in this paper. Furthermore, Doyle et al used average nasal conductance values at three and 10 minutes for comparison, in contrast to the more global AUC or specific PD50 values used in the present study. As subjects differ in their time to peak nasal response after challenge, the selection of isolated time points for analysis may give rise to inaccuracies. The use of all time points as in AUC analysis or individual peak response with frequent measurements after challenge minimises this source of error.

In addition to the influence of agonists on nasal blockage, the comparative effect of bradykinin and histamine on plasma protein exudation was also investigated within the nose. The major change in lavage proteins after challenge was an increase in albumin, the increase being significantly greater with bradykinin than histamine (fig 4A). The present study therefore shows that bradykinin is more potent than histamine in inducing plasma protein leakage from the superficial mucosal vasculature, in addition to its effects on the nasal capacitance vessels. This was only quantified in a single isomolar dose challenge so no mathematical estimate of the
relative potencies can be ascertained for this parameter. This action on vascular protein exudation is likely to be of relevance both to extravascular fluid accumulation in mucosal oedema and to the volume of luminal secretions. In contrast to the relative nasal vascular effects, histamine had a greater effect on rhinorrhoea than bradykinin (fig 2). Although it is possible that long lasting nasal blockage may have reduced the recovery of anterior nasal secretions after bradykinin, it is more likely that histamine, unlike bradykinin,21 induces reflex mediated glandular secretion in addition to inducing vascular permeability changes. Consistent with this, histamine induced a comparable increase in total nasal lavage protein to bradykinin (fig 4B) in the absence of a comparable increase in nasal lavage albumin (fig 4A). The increase in non-albumin proteins is suggestive of glandular secretion rather than extravasation of proteins from the vascular component.22

Evidence for relevant sensory neural stimulation with histamine was apparent in this study, with both itch and sneeze reported after challenge. Neither of these neurally mediated responses occurred with bradykinin challenge and we have previously shown that the rhinorrhoea associated with bradykinin is not inhibited by a muscarinic antagonist23 indicating a non-cholinergic pathway. This, together with the nasal pain and discomfort reported with bradykinin challenge, suggests that bradykinin stimulates a different neural sensory mechanism within the nose from that stimulated by histamine, potentially non-cholinergic, non-adrenergic pathways.

This study therefore provides a potential explanation for the relative lack of effect of H1 antihistamines in the treatment of nasal blockage in rhinitis since bradykinin, which has been found in increased amounts in nasal lavage fluid after allergen challenge in vivo, is more potent than histamine in inducing both nasal obstruction and plasma protein exudation. The development of potent and selective β2 receptor kinin antagonists will allow further evaluation of kinins in nasal airflow obstruction and potentially enhance the treatment of allergic rhinitis.

We are grateful to Dr Andrew Walls for his technical assistance on protein assay and Dr Doreen Ashworth (Ferring Institute) for high performance liquid chromatography analysis of kinins in purity. This study was supported by a grant from the Ferring Peptide Research Partnership, Malmo, Sweden.


